West Pharmaceutical Services Inc. ($WST) Stock Forecast: Up 1.8% Today

What is West Pharmaceutical Services Inc.?

West Pharmaceutical Services (WST): West Pharmaceutical Services is a global leader in innovative solutions for injectable drug administration, with a focus on high-volume therapies such as GLP-1 treatments for diabetes and obesity. The company recently expanded its Dublin facility to meet the increasing demand for integrated drug delivery solutions.

Why is West Pharmaceutical Services Inc. going up?

WST stock is up 1.8% on Apr 1, 2026 16:27

• West Pharmaceutical Services stock experienced a bullish movement, closing 2.24% higher.
• The expansion of the Dublin facility to support high-volume injectable therapies, particularly for diabetes and obesity, likely contributed to investor optimism.
• Despite underperforming the broader market, the company's strategic initiatives, such as the new facility and strong financial performance, have garnered positive attention from analysts and investors.
• The announcement of a $1 billion share buyback and a "Buy" rating with a consensus target price of $314.56 further boosted investor confidence in West Pharmaceutical Services' growth prospects.

WST Price Chart

WST Technical Analysis

WST News

West Pharmaceutical Services opens expanded Dublin facility for injectable therapies

West Pharmaceutical Services announced the opening of an expanded 165,000-square-foot facility for contract services in Dublin, Ireland, creating 330 new jobs. This expansion enhances West's capabilities in high-volume injectable therapies, including GLP-1 treatments for diabetes and obesity, and increases global capacity for integrated drug delivery solutions. The company's comprehensive contract services, West Vantage, aim to accelerate market entry for pharmaceutical and biotechnology partners by providing scalable solutions for life-enhancing therapies.

https://www.drugdeliverybusiness.com/west-pharmaceutical-services-expanded-dublin-facility/

Rockland Trust Co. Has $1.70 Million Position in West Pharmaceutical Services, Inc. $WST

Rockland Trust Co. significantly reduced its stake in West Pharmaceutical Services by 92.6% in the fourth quarter, selling 76,903 shares but still holding 6,163 shares valued at $1.696 million. Despite this, institutional ownership remains high at 93.9%. West Pharmaceutical recently beat earnings estimates, announced a $1 billion share buyback, and analysts maintain a "Buy" rating with a consensus target price of $314.56.

https://www.marketbeat.com/instant-alerts/filing-rockland-trust-co-has-170-million-position-in-west-pharmaceutical-services-inc-wst-2026-04-01/

West Pharmaceutical Services Inc. stock rises Tuesday, still underperforms market

West Pharmaceutical Services Inc. (WST) stock increased by 2.24% on Tuesday, closing at $250.64. Despite this gain, the stock underperformed the broader market, as the S&P 500 Index and Dow Jones Industrial Average saw larger increases of 2.91% and 2.49% respectively. This marks the second consecutive day of gains for West Pharmaceutical Services Inc.

https://www.marketwatch.com/data-news/west-pharmaceutical-services-inc-stock-rises-tuesday-still-underperforms-market-f1983641-e0d4fa688a79?mod=mw_quote_news&gaa_at=eafs&gaa_n=AWEtsqcIinqkrkarFHJs7M6yIyPvkweG-KHY6SKtetOhNJvad7god3XKIq29&gaa_ts=69cd3f99&gaa_sig=XWGaJDXVUKho3-3l2bNzbNek19uOu8NwelG5tot-6OpwMSZZLngoYc1XI3w-fgJJ4QPEUV2kDWXL1MVgspHYFw%3D%3D

West Expands Dublin Facility to Support High-Volume Injectable Therapies, Including Diabetes and Obesity

West Pharmaceutical Services has opened a new 165,000 square foot facility in Dublin, significantly expanding its contract services to meet the growing global demand for high-volume injectable treatments, particularly for diabetes and obesity. This expansion enhances West's capabilities in drug handling, device assembly, and packaging, reinforcing its role in accelerating time to market for life-enhancing therapies. The new facility forms part of West Vantage™, the company's comprehensive contract services business, offering a single-source solution from product conceptualization to regulatory support.

https://www.prnewswire.com/news-releases/west-expands-dublin-facility-to-support-high-volume-injectable-therapies-including-diabetes-and-obesity-302730303.html

In a $3.889B boat market, Twin Vee picks Nautical Ventures

Twin Vee PowerCats Co. (Nasdaq:VEEE) has named Nautical Ventures Group as its exclusive authorized dealer in Broward County, Florida, effective March 31, 2026. This partnership is strategically important given Broward County's $3.889 billion marine market in 2022. The agreement includes initial inventory deliveries in the coming weeks and a collaboration to develop two custom adventure boat models tailored for South Florida.

https://www.stocktitan.net/news/VEEE/twin-vee-power-cats-co-announces-nautical-ventures-as-broward-county-0o0ah5hhcydy.html

Trending Today

SolarEdge Technologies, Inc. ($SEDG) Stock Forecast: Down 7.1% Today

lululemon athletica inc. ($LULU) Stock Forecast: Up 5.4% Today

Mosaic Company (The) ($MOS) Stock Forecast: Down 5.1% Today

Akamai Technologies Inc. ($AKAM) Stock Forecast: Down 5.7% Today

CF Industries Holdings Inc. ($CF) Stock Forecast: Down 5.5% Today

TripAdvisor Inc. ($TRIP) Stock Forecast: Up 5.4% Today

Snowflake Inc ($SNOW) Stock Forecast: Down 11.6% Today

Intel Corporation ($INTC) Stock Forecast: Up 5.1% Today

Gap Inc. ($GAP) Stock Forecast: Up 5.1% Today

PVH Corp. ($PVH) Stock Forecast: Up 5.0% Today

West Pharmaceutical Services Inc. Price History

10.02.2026 - WST Stock was down 5.2%

• The bearish movement in WST stock may be linked to uncertainty surrounding an upcoming CEO transition, as Eric Green, credited with significant company growth, prepares to retire.
• Despite strong Q4 2025 earnings and positive 2026 guidance, concerns about the leadership change and its potential effect on future growth may have prompted investor caution.
• Projected growth in the pharmacy blister packaging market presents potential opportunities for WST, but investor focus on internal company dynamics rather than broader industry trends is evident.
• Valuation concerns, including a high P/E ratio relative to industry norms, could be contributing to the downward pressure on WST stock as investors reevaluate the company's future post-Green's retirement announcement.

13.01.2026 - WST Stock was up 5.2%

• The bullish movement in WST stock today can be attributed to the company's robust Q4 2025 results and optimistic 2026 guidance, which exceeded market expectations and showcased strong revenue growth driven by high-value product components, GLP-1 demand, and biologics recovery.
• Despite concerns raised in previous quarters about slipping net profit margins and trailing revenue growth, the company's forecasted profit for 2026 above estimates, fueled by strong demand for drug components, has instilled confidence in investors and contributed to the stock's positive performance.
• The tension between bullish growth narratives and financial challenges seems to have been alleviated by the company's updated outlook, emphasizing organic net sales growth and highlighting the positive impact of underlying demand and product mix on its future financial prospects.
• Overall, WST's stock surge today reflects investor optimism surrounding the company's ability to capitalize on the expanding GLP-1 market, strategic investments in innovation, and the promising outlook for its high-value product components in the healthcare industry.

01.03.2026 - WST Stock was up 1.8%

• West Pharmaceutical Services stock experienced a bullish movement, closing 2.24% higher.
• The expansion of the Dublin facility to support high-volume injectable therapies, particularly for diabetes and obesity, likely contributed to investor optimism.
• Despite underperforming the broader market, the company's strategic initiatives, such as the new facility and strong financial performance, have garnered positive attention from analysts and investors.
• The announcement of a $1 billion share buyback and a "Buy" rating with a consensus target price of $314.56 further boosted investor confidence in West Pharmaceutical Services' growth prospects.

04.01.2026 - WST Stock was up 5.0%

• West Pharmaceutical Services (WST) witnessed a strong bullish movement in the market today, with the following factors contributing to this positive trend:
• Analysts maintaining a "Buy" consensus rating for WST, setting an average target price of $335.78, reflecting confidence in the company's future performance.
• Truist Financial Corp significantly increased its stake in WST by 73.7% in the third quarter, indicating strong institutional investor confidence in the company's growth prospects.
• Despite a slight decrease in the average one-year price target for WST, the new target still represents a notable 23.61% increase from the latest closing price, showcasing optimism about the company's potential.
• The recent launch of DuPont's new Liveo C6-8XX Liquid Silicone Rubber series for healthcare applications might have indirectly influenced investor sentiment towards WST, highlighting the continuous innovation and advancements in the healthcare sector where WST operates.

06.00.2026 - WST Stock was up 5.7%

• Despite executive insider selling and recent performance challenges, West Pharmaceutical Services Inc. exceeded expectations with its Q3 earnings and revenue. This likely contributed to the positive movement in the company's stock.
• The growing investments from North Growth Management Ltd. and Ethic Inc. in WST suggest increasing confidence in the company's future, especially with the optimistic FY2025 guidance provided.
• Thermo Fisher Scientific Inc. ($TMO) recently announced a quarterly dividend and a stock buyback program, potentially boosting market sentiment towards healthcare companies, including WST.
• In summary, West Pharmaceutical Services Inc.'s bullish stock movement today could be attributed to its strong financial performance, increased stake acquisitions, and positive developments in the healthcare sector.

21.10.2025 - WST Stock was up 5.1%

• The decrease in short interest indicates a positive sentiment among investors towards WST.
• The reduction in shares sold short could suggest that investors are becoming more confident in the company's future prospects.
• This decrease in short interest may have contributed to increased buying pressure on WST, leading to its bullish movement today.

12.01.2026 - WST Stock was down 7.5%

• Today, despite reporting strong Q4 2025 earnings and issuing optimistic guidance for FY 2026, West Pharmaceutical Services (WST) saw a bearish movement in its stock. Possible reasons for this unexpected market reaction include:
• The market potentially factoring in the positive earnings beat and revenue results from Q4 2025, leading to profit-taking.
• Analysts expressing concerns about the high valuation of WST stock, with implications raised by TipRanks' AI Analyst, Spark.
• A slight decrease in operating margin, even though the free cash flow margin improved, raising questions about future profitability and efficiency.
• General market conditions or sector-specific factors that overshadowed West Pharmaceutical Services' positive financial performance.

12.01.2026 - WST Stock was down 3.4%

• Despite posting solid Q4 and 2025 results with strong revenue growth and beating earnings estimates, West Pharmaceutical Services (WST) experienced a bearish movement in the stock market.
• The bearish trend could be linked to an AI Analyst assigning a Neutral rating to WST, citing high valuation concerns despite the company's strong financial performance.
• Moreover, investors seemed worried about the planned divestiture of its SmartDose 3.5mL system, raising uncertainties about future revenue streams and prompting a sell-off.
• In conclusion, while the company showcased robust financial performance and positive 2026 outlook, market sentiment and valuation worries likely played a part in the stock's bearish movement.

06.01.2026 - WST Stock was up 5.2%

• Strong bullish movement in the market today for WST.
• Announcement of an integrated syringe system to streamline pharmaceutical development and supply chain management, with positive industry feedback.
• Expectations of earnings growth and higher revenues for the quarter ended December 2025, despite some analysts expressing dissenting views.
• Anticipation of insights into demand trends for injectable therapies and growth projections in the upcoming earnings reveal.
• WST's commitment to driving innovation in cancer treatment packaging, reflecting dedication to advancing healthcare solutions and making an impact in the fight against cancer.

16.00.2026 - WST Stock was down 4.2%

• Institutional investor Conning Inc. decreased its stake in AbbVie Inc., suggesting a potential shift in focus away from traditional pharmaceutical companies like AbbVie. This shift could impact related stocks such as WST.
• Analysts indicate that WST may be overvalued at its current price. Concerns about revenue headwinds and project conversion risks likely contributed to the stock's bearish movement.
• Despite positive growth prospects in the GLP-1 market and regulatory upgrades, challenges including revenue headwinds and profitability risks may have overshadowed the positive outlook, leading to the bearish market movement.
• The combination of reduced institutional investment in AbbVie, concerns about WST's overvaluation and revenue challenges, and potential risks in project conversions likely influenced the bearish movement in WST's stock today.

23.00.2026 - WST Stock was down 6.9%

• Despite positive developments like the sale of SmartDose rights to AbbVie and a "strong-buy" rating from Zacks Research, WST saw a decline in its market value today.
• The market's negative reaction may be attributed to concerns about the impact of selling a product that contributed significantly to WST's revenue in 2025, leading to uncertainties regarding future earnings.
• While the industry outlook is favorable and growth prospects are promising, investors may be wary of WST's strategic shift and the challenges highlighted in recent reports.
• The extended collaboration between BD and Ypsomed to target the expanding biologics market could intensify competition in the drug delivery systems sector, creating additional pressure on WST's market standing.

06.10.2025 - WST Stock was down 4.0%

• Analysts are bullish on WST, predicting a potential surge of 25.41% in the stock price.
• Despite positive analyst sentiment, the market may have reacted to other factors causing a bearish movement in WST.
• It is possible that external market conditions or unforeseen events impacted WST negatively, leading to the bearish trend observed today.